Volume 7 Issue 137
Published - 14:00 UTC 08:00 EST 17-May-2005 
Next Update - 14:00 UTC 08:00 EST 18-May-2005

Editor: Susan K. Boyer, RN
© Vidyya.
All rights reserved.

We subscribe to the HONcode principles. Verify here.

  

 


Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly

Amgen Inc., announced that final results of a Phase 3 randomized, head-to-head study demonstrated that 200 mcg of Aranesp® (darbepoetin alfa) administered every two weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia. more  

Prescribing information: Aranesp

Aranesp® is indicated for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies. Aranesp is a recombinant erythropoietic protein (a protein that stimulates production of oxygen-carrying red blood cells). Aranesp is approved for multiple indications with varying dosage instructions in the U.S., European Union, Canada and Australia. Aranesp was approved by the FDA in September 2001 for up to every-two-week dosing for the treatment of anemia associated with chronic renal failure, also known as CKD, for patients on dialysis and patients not on dialysis. more

Zevalin safe and effective for non-Hogdkin's lymphoma patients with advanced disease

According to a University of Pittsburgh Medical Center (UPMC) study, patients with advanced non-Hodgkin's lymphoma (NHL) previously treated with chemotherapy and adult stem cell transplantation can safely tolerate ZevalinTM (ibritumomab tiuxetan), a radiolabeled monoclonal antibody that targets radiation directly to a tumor. The study, presented at the 41st annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, indicates that NHL patients who have received prior therapies for their disease respond safely to treatment with Zevalin. more  

Test predicts risk of blood clots in women receiving tamoxifen therapy for breast cancer

Zevalin® (ibritumomab tiuxetan), as part of the ZEVALIN therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular B-cell NHL that is refractory to Rituxan® (rituximab) therapy. more

Anti-depressant use linked to increased GI bleeding  

According to new research presented today at Digestive Disease Week® 2005 (DDW), use of a common type of antidepressant may increase gastrointestinal (GI) bleeding. In fact, the study suggests that the increase is similar to that associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs, known as pain relievers). DDW is the largest international gathering of physicians, academics and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. more

Potential diabetes treatment with transplanted liver cells 

According to a newly published report, researchers have converted adult human liver (AHL) cells expressing the pancreatic and duodenal homeobox gene-1 (PDX-1) into insulin-producing cells that can be transplanted into mice to treat diabetes. more

Subliminal processing of threatening words

Researchers report that individuals can unconsciously process the meaning of subliminal words--addressing a long-standing question in cognitive psychology. more

 

Prescribing information for Aranesp and Zevalin appears in today's issue of Vidyya.